Discovery and development of anti-HBV agents and their resistance (Q33677072)

2 July 2019

4 references

19 September 2019

3 November 2019

27 October 2020

26 October 2022

Discovery and development of anti-HBV agents and their resistance (English)

1 reference

2 July 2019

biomedical investigative technique

main subject

1 reference

19 September 2019

1 reference

3 November 2019

1 reference

27 October 2020

Kyun-Hwan Kim

1

1 reference

2 July 2019

Nam Doo Kim

series ordinal

2

1 reference

2 July 2019

Baik-Lin Seong

series ordinal

3

1 reference

2 July 2019

language of work or name

English

0 references

publication date

27 August 2010

5 references

2 July 2019

19 September 2019

3 November 2019

27 October 2020

26 October 2022

4 references

2 July 2019

19 September 2019

3 November 2019

27 October 2020

15

1 reference

2 July 2019

issue

9

1 reference

2 July 2019

page(s)

5878-5908

1 reference

2 July 2019

Creative Commons Attribution 3.0 Unported

copyright license

4 references

19 September 2019

3 November 2019

27 October 2020

Synthesis and anti-hepatitis B virus activity of novel benzimidazole derivatives

26 October 2022

0 references

1 reference

12 December 2020

Biological profiling of anti-HIV agents and insight into CCR5 antagonist binding using in silico techniques

1 reference

12 December 2020

Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 5-hydroxy-1H-indole-3-carboxylates

1 reference

12 December 2020

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

1 reference

12 December 2020

Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B.

1 reference

12 December 2020

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

1 reference

12 December 2020

Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis

1 reference

12 December 2020

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

1 reference

12 December 2020

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

1 reference

12 December 2020

Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.

1 reference

12 December 2020

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

1 reference

12 December 2020

Inhibition of hepatitis B virus polymerase by entecavir

1 reference

12 December 2020

Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans

1 reference

12 December 2020

Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine

1 reference

12 December 2020

A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes

1 reference

12 December 2020

Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients

1 reference

12 December 2020

The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains

1 reference

12 December 2020

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

12 December 2020

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial

1 reference

12 December 2020

Understanding the molecular basis of HBV drug resistance by molecular modeling

1 reference

12 December 2020

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

12 December 2020

Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication

1 reference

12 December 2020

In silico screening for non-nucleoside HIV-1 reverse transcriptase inhibitors using physicochemical filters and high-throughput docking followed by in vitro evaluation.

1 reference

12 December 2020

Structural insight into processive human mitochondrial DNA synthesis and disease-related polymerase mutations

1 reference

12 December 2020

Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

1 reference

12 December 2020

Anti-hepatitis B virus activity of wogonin in vitro and in vivo

1 reference

12 December 2020

Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system

1 reference

12 December 2020

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

12 December 2020

Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives

1 reference

12 December 2020

Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA.

1 reference

12 December 2020

Hepatitis B virus resistance to nucleos(t)ide analogues.

1 reference

12 December 2020

Natural and iatrogenic variation in hepatitis B virus

1 reference

12 December 2020

Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function.

1 reference

12 December 2020

Anti-HBV and cytotoxic activities of pyranocoumarin derivatives

1 reference

12 December 2020

A genetic algorithm for flexible molecular overlay and pharmacophore elucidation.

1 reference

12 December 2020

Telbivudine in the treatment of chronic hepatitis B.

1 reference

12 December 2020

Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms

1 reference

12 December 2020

Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase

1 reference

12 December 2020

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

1 reference

12 December 2020

Cellular and virological mechanisms of HBV drug resistance

1 reference

12 December 2020

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

1 reference

12 December 2020

Calcium signaling by HBx protein in hepatitis B virus DNA replication

1 reference

12 December 2020

Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus

1 reference

12 December 2020

Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative

1 reference

12 December 2020

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

1 reference

12 December 2020

Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro

1 reference

12 December 2020

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

1 reference

12 December 2020

Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones

1 reference

12 December 2020

Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.

1 reference

12 December 2020

Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil

1 reference

12 December 2020

Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B.

1 reference

12 December 2020

Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy?

1 reference

12 December 2020

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

1 reference

12 December 2020

Synthesis and anti-hepatitis B virus evaluation of novel ethyl 6-hydroxyquinoline-3-carboxylates in vitro

1 reference

12 December 2020

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

12 December 2020

A Substituted Tetrahydro-Tetrazolo-Pyrimidine Is a Specific and Novel Inhibitor of Hepatitis B Virus Surface Antigen Secretion

1 reference

12 December 2020

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.

1 reference

12 December 2020

A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency

1 reference

12 December 2020

Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion

1 reference

12 December 2020

Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus

1 reference

12 December 2020

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

1 reference

12 December 2020

Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives

1 reference

12 December 2020

Pharmacokinetics of LB80331 and LB80317 following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice

1 reference

12 December 2020

Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma

1 reference

12 December 2020

Control of cccDNA function in hepatitis B virus infection.

1 reference

12 December 2020

Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

12 December 2020

RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant.

1 reference

12 December 2020

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

12 December 2020

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

1 reference

12 December 2020

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

1 reference

12 December 2020

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks

1 reference

12 December 2020

Identification of novel HCV RNA-dependent RNA polymerase inhibitors using pharmacophore-guided virtual screening

1 reference

12 December 2020

Robustaflavone, a potential non-nucleoside anti-hepatitis B agent

1 reference

12 December 2020

Mutation rate of the hepadnavirus genome

1 reference

12 December 2020

Antiviral L-nucleosides specific for hepatitis B virus infection

1 reference

12 December 2020

Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

1 reference

12 December 2020

Inhibition of replication of hepatitis B virus by cytallene in vitro

1 reference

12 December 2020

Biology of hepatitis B virus.

1 reference

12 December 2020

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

1 reference

12 December 2020

Anti-HBV agents. Part 2: synthesis and in vitro anti-hepatitis B virus activities of alisol A derivatives

1 reference

12 December 2020

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus

1 reference

12 December 2020

Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease.

1 reference

12 December 2020

Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

12 December 2020

Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants: a molecular dynamics study

1 reference

12 December 2020

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

12 December 2020

2,5-Pyridinedicarboxylic acid derivatives as non-nucleosidic reverse transcriptase inhibitors of hepatitis B virus

1 reference

12 December 2020

Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir

1 reference

12 December 2020

The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging

1 reference

12 December 2020

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

12 December 2020

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

1 reference

12 December 2020

Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue

1 reference

12 December 2020

Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective

1 reference

12 December 2020

Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids

1 reference

12 December 2020

Combining 3-D quantitative structure-activity relationship with ligand based and structure based alignment procedures for in silico screening of new hepatitis C virus NS5B polymerase inhibitors

1 reference

12 December 2020

Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis

1 reference

12 December 2020

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

12 December 2020

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

12 December 2020

A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent

1 reference

12 December 2020

Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir

1 reference

12 December 2020

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

1 reference

12 December 2020

Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations

1 reference

12 December 2020

Pharmacophore-based virtual screening: a review of recent applications

1 reference

12 December 2020

Novel mechanism for reverse transcription in hepatitis B viruses

1 reference

12 December 2020

Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation

1 reference

12 December 2020

Computational model of hepatitis B virus DNA polymerase: molecular dynamics and docking to understand resistant mutations.

1 reference

12 December 2020

Adefovir dipivoxil: a review of its use in chronic hepatitis B.

1 reference

12 December 2020

Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition

1 reference

12 December 2020

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

1 reference

12 December 2020

Strategies in the design of antiviral drugs

1 reference

12 December 2020

The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis

1 reference

12 December 2020

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

12 December 2020

LB80380: a promising new drug for the treatment of chronic hepatitis B

1 reference

12 December 2020

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

12 December 2020

Structure casts light on mtDNA replication.

1 reference

12 December 2020

Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B

1 reference

12 December 2020

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

1 reference

12 December 2020

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

12 December 2020

Drug insight: Nucleoside and nucleotide analog inhibitors for hepatitis B.

1 reference

12 December 2020

Inhibition of hepatitis B virus in mice by RNA interference

1 reference

12 December 2020

Synthesis and antiviral activity of new acrylamide derivatives containing 1,2,3-thiadiazole as inhibitors of hepatitis B virus replication

1 reference

12 December 2020

Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system.

1 reference

12 December 2020

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

12 December 2020

Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors

1 reference

12 December 2020

Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75.

1 reference

12 December 2020

Viral dynamics in hepatitis B virus infection

1 reference

12 December 2020

Anti-HBV agents. Part 3: preliminary structure-activity relationships of tetra-acylalisol A derivatives as potent hepatitis B virus inhibitors

1 reference

12 December 2020

The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro

1 reference

12 December 2020

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression

1 reference

12 December 2020

10.3390/MOLECULES15095878

Identifiers

DOI

1 reference

2 July 2019

PMC publication ID

6257723

1 reference

2 July 2019

PubMed publication ID

20802402

1 reference

2 July 2019